• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    LFW Photonics Market Index
    Markets
    Stocks
    ETFs
    Tools
    Markets:
    Overview
    News
    Currencies
    International
    Treasuries

    Alnylam Pharmaceuticals, Inc. - Common Stock (NQ:ALNY)

    315.53 +13.86 (+4.59%)
    Streaming Delayed Price Updated: 11:19 AM EDT, Jul 2, 2026 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Press Releases about Alnylam Pharmaceuticals, Inc. - Common Stock

    < Previous 1 2 3 4 5 6 7 8 9 Next >
    News headline image
    Alnylam to Host Tenth “RNAi Roundtable” Webcast Series
    From Alnylam Pharmaceuticals, Inc.
    Via Business Wire
    News headline image
    Alnylam and Inceptive Form Strategic AI Collaboration to Accelerate the Discovery of RNAi Therapeutics
    From Alnylam Pharmaceuticals, Inc. and Inceptive
    Via Business Wire
    News headline image
    Alnylam Issues 2025 Corporate Responsibility Report
    From Alnylam Pharmaceuticals, Inc.
    Via Business Wire
    News headline image
    New Data Analyses Presented at Heart Failure 2026 Demonstrate Robust and Consistent Clinical Benefit of Vutrisiran as a First-Line Treatment Option Across ATTR-CM Patient Populations, Including Patients with a High Disease Burden
    From Alnylam Pharmaceuticals, Inc.
    Via Business Wire
    News headline image
    Alnylam to Webcast Presentations at Upcoming Investor Conferences
    From Alnylam Pharmaceuticals, Inc.
    Via Business Wire
    News headline image
    Alnylam to Present New Analyses at Heart Failure 2026 Underscoring Consistent Clinical Profile of Vutrisiran in ATTR-CM
    From Alnylam Pharmaceuticals, Inc.
    Via Business Wire
    News headline image
    Alnylam Pharmaceuticals Reports First Quarter 2026 Financial Results and Highlights Recent Period Progress
    From Alnylam Pharmaceuticals, Inc.
    Via Business Wire
    BioMedNewsBreaks — Oncotelic Therapeutics, Inc. (OTCQB: OTLC) Featured in BioMedWire Editorial Highlighting Biotech’s Shift Toward Science-Driven Asset Valuation
    Via Investor Brand Network
    Topics Artificial Intelligence
    When Science Becomes an Asset: How Advancing Drug Pipelines Are Driving Real-Time Valuation in Biotech
    Via Investor Brand Network
    News headline image
    When Science Becomes an Asset: How Advancing Drug Pipelines Are Driving Real-Time Valuation in Biotech
    From BioMedWire
    Via GlobeNewswire
    News headline image
    Alnylam to Webcast Conference Call Discussing First Quarter 2026 Financial Results
    From Alnylam Pharmaceuticals, Inc.
    Via Business Wire
    News headline image
    New Data Presented at ACC.26 Further Support Benefits of Vutrisiran in ATTR-CM and Potential of Zilebesiran for Hypertension Management
    From Alnylam Pharmaceuticals, Inc.
    Via Business Wire
    News headline image
    Alnylam Advances Future of ATTR-CM Care Through Strategic Collaboration with Viz.ai and Support for the American Heart Association
    From Alnylam Pharmaceuticals, Inc.
    Via Business Wire
    News headline image
    Alnylam to Webcast TTR Investor Webinar
    From Alnylam Pharmaceuticals, Inc.
    Via Business Wire
    News headline image
    Alnylam to Webcast Presentation at TD Cowen 46th Annual Health Care Conference
    From Alnylam Pharmaceuticals, Inc.
    Via Business Wire
    Drug-Delivery Breakthroughs, Cross-Indication Research Accelerate New Momentum in CNS and Oncology Development
    Via Investor Brand Network
    Topics Intellectual Property
    News headline image
    Drug-Delivery Breakthroughs, Cross-Indication Research Accelerate New Momentum in CNS and Oncology Development
    From BioMedWire
    Via GlobeNewswire
    News headline image
    Alnylam Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Highlights Recent Period Progress
    From Alnylam Pharmaceuticals, Inc.
    Via Business Wire
    News headline image
    Alnylam to Webcast Conference Call Discussing Fourth Quarter and Full Year 2025 Financial Results
    From Alnylam Pharmaceuticals, Inc.
    Via Business Wire
    News headline image
    Alnylam Launches “Alnylam 2030” Strategy to Drive Next Era of Growth and Patient Impact
    From Alnylam Pharmaceuticals, Inc.
    Via Business Wire
    News headline image
    Alnylam to Webcast Presentation at 44th Annual J.P. Morgan Healthcare Conference
    From Alnylam Pharmaceuticals, Inc.
    Via Business Wire
    News headline image
    Alnylam to Invest $250 Million to Add Enzymatic Ligation Platform to U.S. Manufacturing Facility to Meet Growing Global Demand for RNAi Therapeutics
    From Alnylam Pharmaceuticals, Inc.
    Via Business Wire
    News headline image
    Alnylam Announces Partial Repurchase of 1.00% Convertible Senior Notes Due 2027
    From Alnylam Pharmaceuticals, Inc.
    Via Business Wire
    News headline image
    Alnylam Pharmaceuticals Announces Changes to Board of Directors
    From Alnylam Pharmaceuticals, Inc.
    Via Business Wire
    News headline image
    New Post Hoc Analysis from the HELIOS-B Phase 3 Study Shows Vutrisiran Improved Measures of Heart Structure and Function in Patients with ATTR-CM
    From Alnylam Pharmaceuticals, Inc.
    Via Business Wire
    News headline image
    Alnylam to Webcast Presentations at Upcoming November Investor Conferences
    From Alnylam Pharmaceuticals, Inc.
    Via Business Wire
    News headline image
    Alnylam Pharmaceuticals Reports Third Quarter 2025 Financial Results and Highlights Recent Period Progress
    From Alnylam Pharmaceuticals, Inc.
    Via Business Wire
    News headline image
    Alnylam to Webcast Conference Call Discussing Third Quarter 2025 Financial Results
    From Alnylam Pharmaceuticals, Inc.
    Via Business Wire
    News headline image
    Alnylam Announces First Patient Dosed in ZENITH Global Phase 3 Cardiovascular Outcomes Trial of Zilebesiran
    From Alnylam Pharmaceuticals, Inc.
    Via Business Wire
    News headline image
    New Data from HELIOS-B Phase 3 Study Demonstrate Lower Rates of Gastrointestinal Events in ATTR-CM Patients Treated with Vutrisiran
    From Alnylam Pharmaceuticals, Inc.
    Via Business Wire
    < Previous 1 2 3 4 5 6 7 8 9 Next >
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the Privacy Policy and Terms Of Service.
    © 2025 FinancialContent. All rights reserved.